Asunto(s)
Proteínas Gestacionales , Huesos/efectos de los fármacos , Huesos/fisiología , Gonadotropina Coriónica/fisiología , Gonadotropina Coriónica/uso terapéutico , Cistinil Aminopeptidasa/sangre , Neoplasias Endometriales/enzimología , Neoplasias Endometriales/genética , Endometrio/enzimología , Femenino , Historia del Siglo XX , Humanos , Subunidad alfa del Factor 1 Inducible por Hipoxia , Hormona Luteinizante/fisiología , Metaloproteinasas de la Matriz/genética , Metaloproteinasas de la Matriz/metabolismo , Metaloproteinasas de la Matriz Secretadas , Trabajo de Parto Prematuro/tratamiento farmacológico , Trabajo de Parto Prematuro/enzimología , Trabajo de Parto Prematuro/fisiopatología , Embarazo , Proteínas Gestacionales/historia , Proteínas Gestacionales/fisiología , Proteínas Gestacionales/uso terapéutico , Factores de Transcripción/fisiologíaRESUMEN
We examined the in vivo effect of 2-amino-4,4alpha-dihydro-4alpha,7-dimethyl-3H-phenoxazine-3- one (Phx) on Meth A carcinoma cells transplanted into BALB/c mice, in terms of both antitumor activity and side effects. Phx, which was synthesized by the reaction of 2-amino-5-methylphenol with bovine hemolysates, was administered i.p. at doses of 1 and 5 mg/kg to BALB/c mice transplanted with Meth A tumor cells. Phx exerted a strong antitumor activity to Meth A tumor growing in the mice as 5-fluorouracil (5-FU) did. The antitumor activity of Phx at the dose of 5 mg/kg was comparable to that of 5-FU at the dose of 7.8 mg/kg. In contrast, unlike 5-FU, Phx did not cause leukopenia while showing a strong antitumor activity. The compound also produced little changes in body weight and no wasting of mice developed. These results show that Phx has strong anti-tumor activity, but exerts lower side effects and suggest that Phx is available for therapeutic purposes in the future.
Asunto(s)
Antineoplásicos/uso terapéutico , Carcinoma/tratamiento farmacológico , Oxazinas/uso terapéutico , Células Tumorales Cultivadas/trasplante , Animales , Antineoplásicos/síntesis química , Peso Corporal/efectos de los fármacos , Femenino , Fluorouracilo/uso terapéutico , Recuento de Leucocitos , Ratones , Ratones Endogámicos BALB C , Trasplante de Neoplasias , Oxazinas/síntesis químicaRESUMEN
Bartter's syndrome is a rare renal disorder, and since there are few case reports of Bartter's syndrome complicating pregnancy are few, the changes of electrolytes and hormonal metabolism during pregnancy are unknown. We describe and discuss the course of pregnancy complicated with Bartter's syndrome.
Asunto(s)
Síndrome de Bartter , Complicaciones del Embarazo , Adulto , Síndrome de Bartter/diagnóstico , Síndrome de Bartter/fisiopatología , Peso Corporal , Femenino , Humanos , Embarazo , Complicaciones del Embarazo/diagnóstico , Complicaciones del Embarazo/fisiopatología , Tercer Trimestre del EmbarazoRESUMEN
In recent years, the localization and function of placental tissue proteins (PPs), extracted by Bohn et al., have been extensively studied, the genetic code has been identified for each of the PPs. The present study was carried out to clarify the mRNA expression and protein localization of PP11, PP12, PP19 at the cell level and also to define PP19 the nature of which has remained obscure. PP19 was said to be placenta-derived S-100P. PP11 mRNA was not expressed in cytotrophoblast-derived normal placental tissue or endometrium-derived normal cells, but was expressed in syncytiotrophoblast-derived normal placental tissue, and in choriocarcinoma and endometrial adenocarcinoma, suggesting its involvement in carcinogenesis. PP12 mRNA was expressed in cytotrophoblast-derived normal placental tissue or endometrium-derived normal cells, but was not expressed in syncytiotrophoblast-derived normal placental tissue, choriocarcinoma or endometrial adenocarcinoma, suggesting that this protein serves in the function of normal cells. PP19 mRNA was expressed in the squamous epithelial cells of the uterine cervix and the villous cells, PP19 was localized in more differentiated regions, where cells tended toward keratinization, in both normal and dysplastic uterine cervices. In squamous cell carcinoma, PP19 was localized in more differentiated cells with a large cytoplasm. PP19 mRNA was not expressed in normal endometrial glands, but was detected in endometrial adenocarcinoma, suggesting its involvement in cell differentiation in cervical epitherial cells.